AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Biohaven Pharmaceutical H... (BHVN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

39.80

0.56 (1.43%)

At close: Feb 20, 2025, 3:59 PM

39.77

-0.06%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	39.01
Market Cap	4.02B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-9.37
PE Ratio (ttm)	-4.25
Forward PE	n/a
Analyst	Buy

Ask	41.53
Volume	380,349
Avg. Volume (20D)	969,591
Open	39.26
Previous Close	39.24
Day's Range	38.70 - 40.01
52-Week Range	26.80 - 62.21
Beta	undefined

About BHVN

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as re...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 23, 2022

Employees 239

Stock Exchange NYSE

Ticker Symbol BHVN

Website https://www.biohavenpharma.com

Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for BHVN stock is "Buy." The 12-month stock price forecast is $61, which is an increase of 53.29% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Biohaven Pharmaceutical Holding Ltd. is scheduled to release its earnings on Mar 3, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+11.19%

Biohaven shares are trading higher after the compa... Unlock content with Pro Subscription

2 months ago

+3.01%

Biohaven shares are trading higher after the company announced it will present expanded safety data from its BHV-7000 multiple-dose studies at the 2024 American Epilepsy Society annual meeting.

News

1 week ago · fool.com

Why Biohaven Stock Triumphed on Tuesday

News of a big and important regulator's move was the electricity that powered Biohaven (BHVN 11.19%) stock to an 11%-plus gain on the second trading day of the week. Its leading investigational drug i...

1 week ago · seekingalpha.com

Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck

Biohaven's NDA for Troriluzole in spinocerebellar ataxia was accepted by the FDA with Priority Review, potentially leading to approval in Q3 2025. BHV-7000, a selective Kv7 activator, is being studied...

2 months ago · benzinga.com

Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval

On Monday, Biohaven Ltd. BHVN revealed clinical and regulatory milestones across its proprietary Molecular Degrader of Extracellular Proteins (MoDE) platform and its glutamate modulation and ion chann...

2 months ago · seekingalpha.com

Biohaven's Revenue Path: SCA And Obesity Therapies

Biohaven's pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treat...

2 months ago · benzinga.com

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity.

2 months ago · benzinga.com

Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.

2 months ago · reuters.com

Biohaven's spinal muscular atrophy drug fails to meet main goal in study

Biohaven said on Monday its experimental treatment for spinal muscular atrophy, a rare nervous system dosorder, helped improve patients' motor function in a late-stage study, but failed to achieve sta...